Clinical characteristics.

Diamond-Blackfan anemia (DBA) is characterized by a profound normochromic and usually macrocytic anemia with normal leukocytes and platelets, congenital malformations in up to 50%, and growth deficiency in 30% of affected individuals. The hematologic complications occur in 90% of affected individuals during the first year of life. The phenotypic spectrum ranges from a mild form (e.g., mild anemia or no anemia with only subtle erythroid abnormalities, physical malformations without anemia) to a severe form of fetal anemia resulting in nonimmune hydrops fetalis. DBA is associated with an increased risk for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors including osteogenic sarcoma.

Diagnosis/testing.

The clinical diagnosis can be established in a proband with macrocytic anemia with onset prior to age one year, no other significant cytopenias, reticulocytopenia, normal marrow cellularity with a paucity of erythroid precursors, and no evidence of another acquired or inherited disorder of bone marrow function.

The molecular diagnosis can be established in a female proband by identification of a heterozygous pathogenic variant in one of the 22 genes associated with DBA.

The molecular diagnosis can be established in a male proband by identification of a heterozygous pathogenic variant in a gene associated with autosomal dominant DBA or identification of a hemizygous pathogenic variant in GATA1 or TSR2 (associated with X-linked inheritance).

Management.

Treatment of manifestations: Corticosteroid treatment, recommended in children older than age 12 months, improves the red blood cell count in approximately 80% of affected individuals. Chronic transfusion with packed red blood cells is necessary during the first year of life to avoid steroid-induced toxicity in those not responsive to a trial of corticosteroids at age 12 months and in individuals who relapse. Hematopoietic stem cell transplantation, the only curative therapy for the hematologic manifestations of DBA, is often recommended for those who are transfusion dependent or develop other cytopenias. Ocular, skeletal, genitourinary, cardiac, and endocrine complications are best managed in collaboration with appropriate subspecialists. Treatment of malignancies should be coordinated by an oncologist. Chemotherapy must be given cautiously as it may lead to prolonged cytopenia and subsequent toxicities.

Prevention of secondary complications: Transfusion-related iron overload is the most common complication in transfusion-dependent individuals. Iron chelation therapy with deferasirox orally or desferrioxamine subcutaneously is recommended after ten to 12 transfusions. Corticosteroid-related side effects must also be closely monitored, especially as related to risk for infection, growth deficiency, and loss of bone density in growing children. Often individuals will be placed on transfusion therapy if these side effects are intolerable.

Surveillance: Complete blood counts several times a year; bone marrow aspirate/biopsy to evaluate morphology and cellularity only in the event of another cytopenia or a change in response to treatment. In steroid-dependent individuals: monitor blood pressure and (in children) growth. Evaluation by an endocrinologist for those who are steroid dependent and those at risk for transfusion iron overload. Cancer surveillance includes history, physical examination, and blood counts every four to six months. If red blood cell, white blood cell, or platelet counts fall rapidly, bone marrow aspirate with biopsy and cytogenetic studies (including karyotype and FISH analysis) to look for acquired abnormalities in chromosomes 5, 7, and 8 that are associated with myelodysplastic syndrome or leukemia.

Agents/circumstances to avoid: Deferiprone for the treatment of iron overload (which can cause neutropenia); infection (especially in individuals on corticosteroids).

Evaluation of relatives at risk: Molecular genetic testing of at-risk relatives of a proband with a known pathogenic variant allows for early diagnosis and appropriate monitoring for bone marrow failure, physical abnormalities, and related cancers.

Pregnancy management: Management by an obstetrician with expertise in high-risk pregnancies and hematologists with experience in bone marrow failure syndromes. During pregnancy the maternal hemoglobin level must be monitored. Use of low-dose aspirin up to 37 weeks' gestation may help prevent vasculo-placental complications in women with a history of a problematic pregnancy.

Genetic counseling.

DBA is most often inherited in an autosomal dominant manner; GATA1-related and TSR2-related DBA are inherited in an X-linked manner.

• Autosomal dominant. Approximately 40%-45% of individuals with autosomal dominant DBA have inherited the pathogenic variant from a parent; approximately 55%-60% have a de novo pathogenic variant. Each child of an individual with autosomal dominant DBA has a 50% chance of inheriting the pathogenic variant.
• X-linked. Males with GATA1- or TSR2-related DBA pass the pathogenic variant to all of their daughters and none of their sons. Women heterozygous for a GATA1 or TSR2 pathogenic variant have a 50% chance of transmitting the pathogenic variant in each pregnancy: males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers and will usually not be affected. Carrier testing of at-risk female relatives is possible if the GATA1 or TSR2 pathogenic variant has been identified in the family.

Once the DBA-causing pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

Suggestive Findings

Diamond-Blackfan anemia (DBA) should be suspected in individuals with the following clinical, laboratory, and histopathologic features, and no evidence of another inherited disorder of bone marrow function.

Clinical features

• Pallor, weakness, failure to thrive
• Growth deficiency (observed in 30%)
• Congenital malformations (observed in ~30%-50%); in particular craniofacial, upper-limb, heart, and genitourinary malformations

Laboratory features

• Macrocytic anemia with no other significant cytopenias
• Increased erythrocyte mean corpuscular volume
• Reticulocytopenia
• Elevated erythrocyte adenosine deaminase activity (eADA) (observed in 80%-85%)
• Elevated hemoglobin F concentration

Histopathology features (bone marrow aspirate)

• Normal marrow cellularity
• Erythroid hypoplasia
• Marked reduction in normoblasts
• Persistence of pronormoblasts on occasion
• Normal myeloid precursors and megakaryocytes

Other. Individuals show no evidence of another inherited disorder of bone marrow function. See Differential Diagnosis.

Establishing the Diagnosis

The clinical diagnosis of DBA can be established in a proband with all of the following clinical, laboratory, and histopathology features:

• Macrocytic anemia with onset prior to age one year
• No other significant cytopenias
• Reticulocytopenia
• Normal marrow cellularity with a paucity of erythroid precursors
• No evidence of another acquired or inherited disorder of bone marrow function (See Differential Diagnosis.)

The molecular diagnosis can be established in a female proband by identification of a heterozygous pathogenic (or likely pathogenic) variant in one of the genes listed in Table 1.

The molecular diagnosis can be established in a male proband by identification of a heterozygous pathogenic (or likely pathogenic) variant in one of the genes listed in Table 1 associated with autosomal dominant inheritance, or a hemizygous pathogenic (or likely pathogenic) variant in GATA1 or TSR2 associated with X-linked inheritance.

Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) The identification of variant(s) of uncertain significance cannot be used to confirm or rule out the diagnosis.

Molecular testing approaches usually begin with a multigene panel with analysis of DBA-related genes (rare DBA-related genes may not be included in a panel). Failure to identify a gene can be followed by more comprehensive genomic testing [Ulirsch et al 2018].

• A multigene panel that includes the genes in Table 1 and other genes of interest (see Differential Diagnosis). Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel, custom phenotype-focused exome analysis, and re-analysis of genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
  For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
• More comprehensive genomic testing (when available) including exome sequencing or genome sequencing may be considered if a multigene panel fails to confirm a diagnosis in an individual with features of DBA.
  For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Clinical Description

Diamond-Blackfan anemia (DBA) is characterized by early-onset hypoplastic anemia. Congenital anomalies are observed in approximately 50% of affected individuals and more than one anomaly is observed in up to 25% of individuals. Additional features include growth deficiency and predisposition to malignancy.

Anemia. The primary hematologic feature of DBA is a profound normochromic, macrocytic anemia with normal leukocytes and platelets. The hematologic complications of DBA occur in 90% of affected individuals during the first year of life: the median age at presentation is two months and the median age at diagnosis is three months [Bagby et al 2004, Ohga et al 2004]. Treatment with corticosteroids is recommended in children older than age 12 months (see Management). Approximately 70% of individuals respond but eventually 40% remain steroid dependent and 40% become transfusion dependent; 20% go into remission [Chen et al 2005, Vlachos et al 2008].

Craniofacial features include microcephaly; hypertelorism, epicanthus, ptosis; microtia, low-set ears; broad, depressed nasal bridge; cleft lip/palate, high arched palate; micrognathia; low anterior hairline.

Eye findings include congenital glaucoma, congenital cataract, strabismus.

Neck. Features include webbing, short neck, Klippel-Feil anomaly, Sprengel deformity.

Upper limb and hand including thumb. Findings include absent radial artery; flat thenar eminence; triphalangeal, duplex, bifid, hypoplastic, or absent thumb.

Genitourinary findings include absent kidney, horseshoe kidney; hypospadias.

Heart findings include ventricular septal defect, atrial septal defect, coarctation of the aorta, other cardiac anomalies.

Growth deficiency. Low birth weight was reported in 25% of affected infants. Thirty percent of affected individuals have growth deficiency. Growth deficiency can be influenced by other factors including steroid treatment [Chen et al 2005, Vlachos et al 2008].

Malignancy. DBA is associated with an increased risk for acute myelogenous leukemia, myelodysplastic syndrome, and solid tumors including osteogenic sarcoma [Janov et al 1996, Vlachos et al 2001, Vlachos et al 2012, Alter et al 2018].

Development. Rarely, developmental delay can occur [Kuramitsu et al 2012].

The phenotypic spectrum is broad. Within the same family, affected individuals can have typical DBA or atypical phenotypes including (1) mild anemia; (2) no anemia with only subtle erythroid abnormalities such as macrocytosis, elevated erythrocyte adenosine deaminase activity, and/or increased hemoglobin F concentration; or (3) physical malformations without anemia. Others may have a severe form presenting with fetal anemia that results in nonimmune hydrops fetalis [Dunbar et al 2003, Saladi et al 2004]. Onset of atypical DBA can be later than age one year.

Phenotype Correlations by Gene

RPL5. Craniofacial, congenital heart, and thumb defects were more severe than those seen with pathogenic variants in RPL11 and RPS19 [Gazda et al 2008, Quarello et al 2010]. Cleft lip and/or cleft palate (CL/P) was reported in 45% of affected persons with RPL5 pathogenic variants [Gazda et al 2008] and in 50% of an affected group of Italians with RPL5 pathogenic variants [Quarello et al 2010]. Small gestational age was reported in seven (~88%) of eight individuals with an RPL5 pathogenic variant versus 43% of individuals with an RPS19 pathogenic variant [Cmejla et al 2009].

RPL11. Pathogenic variants in RPL11 are predominantly associated with thumb abnormalities [Gazda et al 2008, Cmejla et al 2009].

Genotype-Phenotype Correlations

Many pathogenic variants are unique to a family and no genotype-phenotype correlations have been confirmed.

Penetrance

Penetrance is almost complete with loss-of-function variants in RPL5, RPS19, and RPS26. Penetrance is high with loss-of-function variants in other genes that encode ribosomal subunits. Missense variants (e.g., of RPS19) appear to be less penetrant [Ulirsch et al 2018].

Nomenclature

Diamond-Blackfan anemia has previously been known as congenital hypoplastic anemia of Blackfan and Diamond, congenital hypoplastic anemia, Blackfan-Diamond syndrome, Aase syndrome, and Aase-Smith syndrome II.

Prevalence

The incidence of DBA is estimated at between 1:100,000 and 1:200,000 live births; incidence remains consistent across ethnicities [Vlachos et al 2008].

Transient Erythroblastopenia of Childhood

Transient erythroblastopenia of childhood (TEC) (OMIM 227050) is characterized by acquired anemia caused by decreased production of red blood cell precursors in a previously healthy child. The etiology of TEC is unknown, although an association with viral infections has been proposed. TEC is almost always self-resolving within one to several months and only requires clinical intervention (red blood cell transfusion) in severe cases. Features that distinguish TEC from DBA include older age at diagnosis: more than 80% of children with TEC are age one year or older at diagnosis. Only 10% of children with TEC have elevated erythrocyte adenosine deaminase activity. In children with TEC, anemia is normocytic.

Other Genetic Conditions with Bone Marrow Failure

Acquired Conditions with Bone Marrow Failure

Infections

• Parvovirus B19 infection; usually asymptomatic, but occasionally can cause red cell aplasia, which is most often mild and self-limited by production of virus-neutralizing antibodies in the host [Parekh et al 2005]. However, in persons with hereditary or acquired anemia, parvovirus infection can be severe and life-threatening, requiring red blood cell transfusions. Seropositivity for parvovirus reaches 50% by age 15 years and 90% in the elderly.
• HIV; associated with pure red cell aplasia (PRCA)
• Viral hepatitis
• Mononucleosis and human T-cell lymphotropic virus type 1

Drugs and toxins

• Anti-seizure medications: diphenylhydantoin, sodium valproate, carbamazepine, sodium dipropylacetate
• Others: azathioprine; chloramphenicol and thiamphenicol; sulfonamides; isoniazid; procainamide

Immune-mediated diseases

• Thymoma, most commonly associated with PRCA. Approximately 5%-10% of persons with thymoma develop PRCA.
• Myasthenia gravis, systemic lupus erythematosus, and multiple endocrinopathies

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with Diamond-Blackfan anemia (DBA), the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Treatment of Manifestations

Anemia. Corticosteroids can initially improve the red blood count in approximately 80% of affected individuals.

• The recommended corticosteroid is prednisone with a starting dose of 2 mg/kg/day given orally once a day in the morning, beginning after age 12 months and ten days to two weeks after a transfusion. An increase in hemoglobin and reticulocyte count is usually seen in two to four weeks. If there is no response by three weeks, steroids can be tapered over two weeks.
• Corticosteroids may be slowly tapered to the minimal effective dose. Monitoring of blood counts is needed to ensure that the red cell hemoglobin concentration remains at 80-100 g/L, the minimum required for transfusion independence.
• The corticosteroid maintenance dose varies and can be extremely low in some individuals. Concerns about the long-term effects of steroids have led to the recommendation of 0.25 mg/kg/day as a preferable maximum daily dose.
• If after approximately one month the recommended steroid dose does not sustain the red cell hemoglobin concentration in an acceptable range, the corticosteroids should be tapered and discontinued.

Side effects of corticosteroids include osteoporosis, weight gain, cushingoid appearance, hypertension, diabetes mellitus, growth restriction, pathologic bone fractures, gastric ulcers, cataracts, glaucoma, and increased susceptibility to infection.

Red blood cell transfusion. If the individual is resistant to corticosteroid therapy, chronic transfusion with packed red blood cells is necessary. The goal of transfusion therapy is a red cell hemoglobin concentration of 80-100 g/L, which is usually adequate for maintaining growth and development.

Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for DBA. Persons with DBA who are transfusion dependent or develop other cytopenias are often treated with HSCT.

In one study of 61 persons with DBA who underwent bone marrow transplantation (BMT), the majority (67%) received their bone marrow grafts from an HLA-matched related donor. The three-year probability of overall survival was 64% (range 50%-74%). Transplantation from an HLA-identical sib donor was associated with better survival [Roy et al 2005].

The Diamond-Blackfan Anemia Registry of North America describes 36 individuals who underwent HSCT: 21 HLA-matched sib HSCTs and 15 alternative donor HSCTs. Survival greater than five years from HSCT for allogeneic sib transplants was 72.7% ±10.7% versus survival greater than five years from alternative donor transplants of 17.1% ±11.9% [Lipton et al 2006, Vlachos et al 2008]. Survival was the best (92.3%) for children younger than age ten years transplanted using an HLA-matched sib.

In a French/German HSCT study of 70 children with DBA, a matched sib donor was available for 45 individuals, a 10/10 HLA matched unrelated donor in 12 individuals, a 9/10 HLA matched unrelated donor in seven individuals, and a less compatible or incomplete HLA matched donor in six individuals. Overall survival was 91% with no difference by donor type. All individuals engrafted; one individual had secondary graft failure. The difference in chronic GVHD between children transplanted before age ten years compared with older individuals did not reach statistical significance.

Note: (1) It is recommended that the affected individual, sibs, and parents undergo HLA typing at the time of diagnosis of DBA to identify the most suitable bone marrow donor in the event that HSCT would be required. (2) Because penetrance of DBA is incomplete, it is possible that a relative considered as a bone marrow donor could have a pathogenic variant but not manifest findings of DBA. (3) Relatives with a pathogenic variant, regardless of their clinical status, are not suitable bone marrow donors, because their donated bone marrow may fail or not engraft in the recipient.

Treatment of other manifestations

• Glaucoma and cataract. As recommended by ophthalmologist
• Skeletal anomalies. Surgical management of thumb anomalies as recommended by orthopedist; occupational and physical therapy as needed
• Genitourinary malformations. Managed as recommended by nephrologist and/or urologist
• Congenital heart defects. As recommended by cardiologist
• Cancer. Treatment of malignancies coordinated by oncologist

Prevention of Secondary Complications

Transfusion iron overload is the most common complication in transfusion-dependent individuals. The following methods are used both to assess for evidence of transfusion iron overload and to evaluate the effectiveness of iron chelation therapy:

• Measurement of iron concentration in a liver biopsy specimen, which accurately determines total body iron accumulation
• T₂*-weighted MRI for assessing iron loading in the liver and heart
• Magnetic biosusceptometry (SQUID), which gives a measurement of hepatic iron concentration

Note: (1) Although the latter two methods of total iron measurement are noninvasive, SQUID is not widely available. MRI is now more widely available and referral to a center with experience in this technique is advisable to obtain a baseline measurement and to more conveniently follow progress after starting chelation therapy. Although liver biopsy is the "gold standard" [Cappellini & Piga 2008, Vlachos et al 2008] it is not a practical choice for long-term follow up. (2) Routine measurement of serum ferritin concentration is not reliable in detecting iron overload because the serum ferritin concentration does not always correlate with total body iron accumulation.

Iron chelation therapy is usually started after ten to 12 transfusions (170-200 mL/kg of packed red blood cells), when serum ferritin concentration reaches 1,000-1,500 µg/L, or when hepatic iron concentration reaches 6-7 mg/g of dry weight liver tissue.

• Deferasirox is recommended in individuals age two years or older. It is administered once daily in an oral dose of 20-30 mg/kg/day. Side effects are usually mild and include rash, nausea, creatinine elevation, and rarely proteinuria and transaminase elevation. In affected individuals, satisfaction with deferasirox is greater than with desferrioxamine, mostly because of ease of administration [Cappellini & Piga 2008, Porter et al 2008, Vlachos et al 2008].
• Desferrioxamine is administered four to seven nights a week in an eight- to 12-hour subcutaneous infusion via a portable pump. The recommended initial dose is 40 mg/kg/day; the maximum dose is 50-60 mg/kg/day. The dose and frequency of infusion may be modified using the serum ferritin concentration or the hepatic iron concentration as a guide [Cappellini & Piga 2008, Vlachos et al 2008]. Side effects include ocular and auditory toxicity and growth deficiency. Compliance rate is hampered by the demanding administration route and schedule.

Note: Deferiprone is not recommended in the treatment of iron overload in individuals with DBA [Vlachos et al 2008] because its side effects include neutropenia [Henter & Karlen 2007].

Side effects of corticosteroids include osteoporosis, weight gain, cushingoid appearance, hypertension, diabetes mellitus, growth deficiency, pathologic bone fractures, gastric ulcers, cataracts, glaucoma, and increased susceptibility to infection [Alter & Young 1998, Willig et al 1999, Lipton et al 2006].

One of the critical side effects of corticosteroids is growth deficiency. If growth is severely impaired, corticosteroids should be stopped and replaced by a short-term red blood cell transfusion regimen [Vlachos et al 2008].

Surveillance

The following are indicated:

• Complete blood counts several times a year
• Bone marrow aspirate/biopsy to evaluate morphology and cellularity, if evidence of another cytopenia or failure of current treatment is noted
• Monitoring of blood pressure in individuals who are steroid dependent
• Monitoring of growth in individuals who are steroid dependent and in those at risk for transfusion iron overload
• Evaluation by an endocrinologist; recommended for individuals who are steroid dependent and those at risk for transfusion iron overload

Cancer surveillance includes the following:

• In individuals with DBA who are otherwise healthy, every four to six months: an interim history, physical examination, and measurement of blood count
• If red blood cell, white blood cell, or platelet counts fall rapidly, bone marrow aspirate with biopsy and cytogenetic studies (including karyotype and FISH analysis) to look for acquired abnormalities in chromosomes 5, 7, and 8 that are associated with certain cancers [Vlachos et al 2008]

Agents/Circumstances to Avoid

Deferiprone is not recommended in the treatment of iron overload in persons with DBA because its side effects include neutropenia [Vlachos et al 2008].

Individuals with DBA, especially those on corticosteroid treatment, should take reasonable precautions to avoid infections, as steroid-dependent individuals are more prone to complications resulting from immune system dysfunction.

Evaluation of Relatives at Risk

It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an affected individual to allow early diagnosis and appropriate monitoring for bone marrow failure, physical abnormalities, and related cancers. Evaluations include:

• Molecular genetic testing if the pathogenic variant in the family is known;
• Consideration of other testing (e.g., mean corpuscular volume, erythrocyte adenosine deaminase activity, and/or fetal hemoglobin concentration) if the pathogenic variant in the family is not known – especially of relatives being considered as bone marrow donors [Vlachos et al 2008].

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

Management of pregnancy in women with DBA requires obstetricians with expertise in high-risk pregnancies and hematologists with experience with bone marrow failure syndromes [Alter et al 1999, Taher et al 2020].

During pregnancy the maternal hemoglobin level must be monitored.

Use of low-dose aspirin up to 37 weeks' gestation may help prevent vasculo-placental complications in women with a history of a previous problematic pregnancy [Faivre et al 2006].

A study that surveyed 64 pregnancies in women with DBA found a high incidence of complications in both mothers and children. Risks include the following [Faivre et al 2006]:

• Intrauterine growth restriction
• Preeclampsia
• Retroplacental hematoma
• In utero fetal death
• Preterm delivery

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Mode of Inheritance

Most often, Diamond-Blackfan anemia (DBA) is inherited in an autosomal dominant manner. GATA1-related DBA and TSR2-related DBA are inherited in an X-linked manner.

Autosomal Dominant Inheritance – Risk to Family Members

Parents of a proband

• Approximately 40%-45% of individuals diagnosed with autosomal dominant DBA inherited a DBA-causing pathogenic variant from a parent who may or may not have manifestations of DBA [Orfali et al 2004].
• Approximately 55%-60% of individuals diagnosed with autosomal dominant DBA have the disorder as the result of a de novo pathogenic variant.
• If the proband appears to be the only affected family member (i.e., a simplex case), molecular genetic testing is recommended for the parents of the proband to confirm their genetic status and to allow reliable recurrence risk counseling.
  Note: If a pathogenic variant has not been identified in the proband, other testing options for the parents can be considered (e.g., mean corpuscular volume, erythrocyte adenosine deaminase activity, and/or fetal hemoglobin concentration).
• If the pathogenic variant identified in the proband is not identified in either parent, the following possibilities should be considered:
  • The proband has a de novo pathogenic variant. Note: A pathogenic variant is reported as "de novo" if: (1) the pathogenic variant found in the proband is not detected in parental DNA; and (2) parental identity testing has confirmed biological maternity and paternity. If parental identity testing is not performed, the variant is reported as "assumed de novo" [Richards et al 2015].
  • The proband inherited a pathogenic variant from a mosaic parent. Parental germline mosaicism is suggested in a family described by Cmejla et al [2000] in which neither parent of two affected sibs had the DBA-causing pathogenic variant identified in the affected sibs. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ cells only.
  • The proband inherited a DBA-causing pathogenic variant from a parent who subsequently developed somatically acquired loss of heterozygosity with preferential loss of the chromosome with the DBA-causing pathogenic variant. This scenario may cause a false negative molecular result when testing leukocyte DNA (see Molecular Pathogenesis) [Venugopal et al 2017, Garelli et al 2019].
• The family history of some individuals diagnosed with DBA may appear to be negative because of failure to recognize the disorder in family members, reduced penetrance, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing has demonstrated that neither parent is heterozygous for the pathogenic variant identified in the proband.

Sibs of a proband. The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:

• If a parent of the proband is affected with autosomal dominant DBA and/or is known to have the pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.
• The penetrance of DBA in heterozygous sibs is high but may vary somewhat depending on the familial pathogenic variant (see Penetrance). In affected heterozygous sibs, the clinical manifestations of DBA are unpredictable and can range, in the same family, from typical and atypical DBA phenotypes to a severe form presenting with fetal anemia resulting in nonimmune hydrops fetalis (see Clinical Description).
• If the DBA-causing pathogenic variant found in the proband is not detected in the leukocyte DNA of either parent, the recurrence risk to sibs is presumed to be slightly greater than that of the general population for one of two possible reasons:
  • Parental germline mosaicism for the DBA-causing pathogenic variant [Cmejla et al 2000]; or
  • A false negative result in a parent due to preferential loss of the chromosome with the DBA-causing pathogenic variant (see Molecular Pathogenesis).
• If the parents have not been tested for the DBA-causing pathogenic variant but are clinically unaffected, sibs are still presumed to be at increased risk for DBA for one of two possible reasons:
  • A parent has germline mosaicism; or
  • A parent is heterozygous but does not have apparent manifestations of DBA because of reduced penetrance or variable expressivity.

Offspring of a proband. Each child of an individual with autosomal dominant DBA has a 50% chance of inheriting the DBA-causing pathogenic variant.

Other family members. The risk to other family members depends on the genetic status of the proband's parents: if a parent has a DBA-causing pathogenic variant, the parent's family members may be at risk.

X-Linked Inheritance – Risk to Family Members

Parents of a male proband

• The father of a male with GATA1- or TSR2-related DBA will not have the disorder nor will he be hemizygous for the pathogenic variant; therefore, he does not require further evaluation/testing.
• In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote. Note: If a woman has more than one affected child and no other affected relatives and if the GATA1 or TSR2 pathogenic variant cannot be detected in her leukocyte DNA, she most likely has germline mosaicism. (No data on the possibility or frequency of germline mosaicism in the mother are available.)
• If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote, the affected male may have a de novo GATA1 or TSR2 pathogenic variant (in which case the mother is not a carrier), or the mother may have somatic/germline mosaicism. (The frequency of de novo pathogenic variants is not currently known.)
• Molecular genetic testing of the mother is recommended to confirm her genetic status and to allow reliable recurrence risk assessment.

Sibs of a male proband. The risk to sibs of a male proband depends on the genetic status of the mother:

• If the mother of an affected male has a GATA1 or TSR2 pathogenic variant, the chance of transmitting it in each pregnancy is 50%.
  • Males who inherit the pathogenic variant will be affected;
  • Females who inherit the pathogenic variant will be heterozygotes and will usually not be affected.
• If the proband represents a simplex case (i.e., a single occurrence in a family) and if the GATA1 or TSR2 pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is presumed to be low but greater than that of the general population because of the possibility of maternal germline mosaicism.

Offspring of a male proband. Affected males transmit the GATA1 or TSR2 pathogenic variant to all of their daughters and none of their sons.

Other family members. The maternal aunts and maternal cousins of a male proband may be at risk of having a GATA1 or TSR2 pathogenic variant.

Note: Molecular genetic testing may be able to identify the family member in whom a de novo pathogenic variant arose, information that could help determine the genetic risk status of the extended family.

Heterozygote detection. Identification of female heterozygotes is possible once a GATA1 or TSR2 pathogenic variant has been identified in an affected family member.

Note: Females who are heterozygous for X-linked DBA will usually not be affected.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

DNA banking. Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see Huang et al [2022].

Prenatal Testing and Preimplantation Genetic Testing

Once the DBA-causing pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing for DBA are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

Ribosomes, consisting of a small 40S subunit and a large 60S subunit, catalyze protein synthesis. Small and large subunits are composed of four RNA species and approximately 80 structurally distinct ribosomal proteins (RPs). The proteins encoded by RPS19, RPS24, RPS17, RPS15, RPS7, RPS27A, RPS10, and RPS26 belong to the small ribosomal subunit, whereas those encoded by RPL5, RPL11, RPL26, RPL35A, and RPL36 are components of the large ribosomal subunit.

RPS19 protein has been demonstrated to play an important role in 18S rRNA maturation in yeast and in human cells [Léger-Silvestre et al 2005, Choesmel et al 2007, Flygare et al 2007, Idol et al 2007]. Similarly, alterations of pre-RNA processing of small or large RP subunit synthesis were demonstrated in human cells with RPS24 and RPS7 deficiency and with RPL35A, RPL5, RPL11, and RPL26 deficiency, respectively, further indicating that DBA is a disorder of ribosomes [Choesmel et al 2008, Farrar et al 2008, Gazda et al 2008, Gazda et al 2012]. Deficiency of RPS19 and RPL35A was shown to cause increased apoptosis in hematopoietic cell lines and in bone marrow cells [Farrar et al 2008, Miyake et al 2008], and imbalance of the p53 family proteins has been suggested as a mechanism of abnormal embryogenesis and anemia in zebrafish on perturbation of RPS19 expression [Danilova et al 2008].

Mechanism of disease causation. Rarely, missense variants may act in a dominant-negative manner, but haploinsufficiency of a ribosomal protein is the most common mechanism. Evidence suggests that ribosomal stress due to ribosome deficiency leads to stabilization of p53 and consequent p53-mediated cell cycle arrest or apoptosis. Furthermore GATA1, a critical erythroid transcription factor, has a complex 5' UTR and is poorly translated when ribosomal proteins are deficient. This can explain why GATA1 pathogenic variants result in a DBA phenotype [Ludwig et al 2014].

Gene-specific laboratory technical considerations. Revertant mosaicism (e.g., acquired uniparental disomy ablating a de novo RPS19 pathogenic variant) has rarely been observed to account for spontaneous remission in individuals with DBA [Venugopal et al 2017, Garelli et al 2019].

Acknowledgments

The author acknowledges the generous support of the Diamond Blackfan Anemia Foundation.

Author History

Catherine Clinton, MS, CGC; Dana-Farber/Boston Children's Cancer and Blood Disorders Center (2009-2021)
Hanna T Gazda, MD, PhD; Boston Children's Hospital (2009-2021)
Colin Sieff, MBBCh, FRCPath (2021-present)

Revision History

• 23 March 2023 (sw) Revision: information regarding GATA1-related cytopenia added to Table 1
• 17 June 2021 (sw) Comprehensive update posted live
• 7 March 2019 (aa) Revision: RPL18, RPL35, and RPS15A added
• 7 April 2016 (sw) Comprehensive update posted live
• 16 January 2014 (cd) Revision: mutation of RPL15 causative of DBA12
• 25 July 2013 (me) Comprehensive update posted live
• 27 January 2011 (me) Comprehensive update posted live
• 24 November 2009 (cd) Revision: deletion/duplication analysis for RPS19 available clinically
• 13 October 2009 (cd) Revision: sequence analysis and prenatal testing available for RPL5, RPL11, RPL35A, RPS7, RPS17 mutations; prenatal testing available for RPS24 mutations
• 25 June 2009 (et) Review posted live
• 17 February 2009 (hg) Original submission

Literature Cited

• Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103:30–9. [PMC free article: PMC5777188] [PubMed: 29051281]
• Alter BP, Kumar M, Lockhart LL, Sprinz PG, Rowe TF. Pregnancy in bone marrow failure syndromes: Diamond-Blackfan anaemia and Shwachman-Diamond syndrome. Br J Haematol. 1999;107:49–54. [PubMed: 10520024]
• Alter BP, Young NS. The bone marrow failure syndromes. In: Nathan DG, Orkin HS, eds. Hematology of Infancy and Childhood. Vol 1. Philadelphia, PA: Saunders; 1998:237-335.
• Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology Am Soc Hematol Educ Program. 2004;1:318–36.
• Ball SE, McGuckin CP, Jenkins G, Gordon-Smith EC. Diamond-Blackfan anaemia in the U.K.: analysis of 80 cases from a 20-year birth cohort. Br J Haematol. 1996;94:645–53. [PubMed: 8826887]
• Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient abnormal myelopoiesis and AML in Down syndrome: an update. Curr Hematol Malig Rep. 2016;11:333–41. [PMC free article: PMC5031718] [PubMed: 27510823]
• Cappellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med. 2008;8:663–74. [PubMed: 18991652]
• Chen S, Warszawski J, Bader-Meunier B, Tchernia G, Da Costa L, Marie I, Dommergues JP. Diamond-blackfan anemia and growth status: the French registry. J Pediatr. 2005;147:669–73. [PubMed: 16291361]
• Choesmel V, Bacqueville D, Rouquette J, Noaillac-Depeyre J, Fribourg S, Cretien A, Leblanc T, Tchernia G, Da Costa L, Gleizes PE. Impaired ribosome biogenesis in Diamond-Blackfan anemia. Blood. 2007;109:1275–83. [PMC free article: PMC1785132] [PubMed: 17053056]
• Choesmel V, Fribourg S, Aguissa-Toure AH, Pinaud N, Legrand P, Gazda HT, Gleizes PE. Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder. Hum Mol Genet. 2008;17:1253–63. [PubMed: 18230666]
• Cmejla R, Blafkova J, Stopka T, Zavadil J, Pospisilova D, Mihal V, Petrtylova K, Jelinek J. Ribosomal protein S19 gene mutations in patients with diamond-blackfan anemia and identification of ribosomal protein S19 pseudogenes. Blood Cells Mol Dis. 2000;26:124–32. [PubMed: 10753603]
• Cmejla R, Cmejlova J, Handrkova H, Petrak J, Petrtylova K, Mihal V, Stary J, Cerna Z, Jabali Y, Pospisilova D. Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia. Hum Mutat. 2009;30:321–7. [PubMed: 19191325]
• Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood. 2008;112:5228–37. [PubMed: 18515656]
• Dunbar AE 3rd, Moore SL, Hinson RM. Fetal Diamond-Blackfan anemia associated with hydrops fetalis. Am J Perinatol. 2003;20:391–4. [PubMed: 14655096]
• Faivre L, Meerpohl J, Da Costa L, Marie I, Nouvel C, Gnekow A, Bender-Götze C, Bauters F, Coiffier B, Peaud PY, Rispal P, Berrebi A, Berger C, Flesch M, Sagot P, Varet B, Niemeyer C, Tchernia G, Leblanc T. High-risk pregnancies in Diamond-Blackfan anemia: a survey of 64 pregnancies from the French and German registries. Haematologica. 2006;91:530–3. [PubMed: 16537118]
• Farrar JE, Nater M, Caywood E, McDevitt MA, Kowalski J, Takemoto CM, Talbot CC Jr, Meltzer P, Esposito D, Beggs AH, Schneider HE, Grabowska A, Ball SE, Niewiadomska E, Sieff CA, Vlachos A, Atsidaftos E, Ellis SR, Lipton JM, Gazda HT, Arceci RJ. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood. 2008;112:1582–92. [PMC free article: PMC2518874] [PubMed: 18535205]
• Flygare J, Aspesi A, Bailey JC, Miyake K, Caffrey JM, Karlsson S, Ellis SR. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood. 2007;109:980–6. [PMC free article: PMC1785147] [PubMed: 16990592]
• Garelli E, Quarello P, Giorgio E, Carando A, Menegatti E, Mancini C, Di Gregorio E, Crescenzio N, Palumbo O, Carella M, Dimartino P, Pippucci T, Dianzani I, Ramenghi U, Brusco A. Spontaneous remission in a Diamond-Blackfan anaemia patient due to a revertant uniparental disomy ablating a de novo RPS19 mutation. Br J Haematol. 2019;185:994–8. [PubMed: 30460677]
• Gazda HT, Preti M, Sheen MR, O'Donohue MF, Vlachos A, Davies SM, Kattamis A, Doherty L, Landowski M, Buros C, Ghazvinian R, Sieff CA, Newburger PE, Niewiadomska E, Matysiak M, Glader B, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH. Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia. Hum Mutat. 2012;33:1037–44. [PMC free article: PMC3370062] [PubMed: 22431104]
• Gazda HT, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Zaucha JM, Glader B, Niemeyer C, Meerpohl JJ, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 2008;83:769–80. [PMC free article: PMC2668101] [PubMed: 19061985]
• Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007;109:5157–9. [PubMed: 17344464]
• Huang SJ, Amendola LM, Sternen DL. Variation among DNA banking consent forms: points for clinicians to bank on. J Community Genet. 2022;13:389–97. [PMC free article: PMC9314484] [PubMed: 35834113]
• Idol RA, Robledo S, Du HY, Crimmins DL, Wilson DB, Ladenson JH, Bessler M, Mason PJ. Cells depleted for RPS19, a protein associated with Diamond Blackfan anemia, show defects in 18S ribosomal RNA synthesis and small ribosomal subunit production. Blood Cells Mol Dis. 2007;39:35–43. [PubMed: 17376718]
• Janov AJ, Leong T, Nathan DG, Guinan EC. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore). 1996;75:77–8. [PubMed: 8606629]
• Kuramitsu M, Sato-Otsubo A, Morio T, Takagi M, Toki T, Terui K, Wang R, Kanno H, Ohga S, Ohara A, Kojima S, Kitoh T, Goi K, Kudo K, Matsubayashi T, Mizue N, Ozeki M, Masumi A, Momose H, Takizawa K, Mizukami T, Yamaguchi K, Ogawa S, Ito E, Hamaguchi I. Extensive gene deletions in Japanese patients with Diamond Blackfan anemia. Blood. 2012;119:2376–84. [PubMed: 22262766]
• Léger-Silvestre I, Caffrey JM, Dawaliby R, Alvarez-Arias DA, Gas N, Bertolone SJ, Gleizes PE, Ellis SR. Specific role for yeast homologs of the Diamond Blackfan anemia-associated Rps19 protein in ribosome synthesis. J Biol Chem. 2005;280:38177–85. [PubMed: 16159874]
• Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;46:558–64. [PubMed: 16317735]
• Ludwig LS, Gazda HT, Eng JC, Eichhorn SW, Thiru P, Ghazvinian R, George TI, Gotlib JR, Beggs AH, Sieff CA, Lodish HF, Lander ES, Sankaran VG. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med. 2014;20:748–53. [PMC free article: PMC4087046] [PubMed: 24952648]
• Miyake K, Utsugisawa T, Flygare J, Kiefer T, Hamaguchi I, Richter J, Karlsson S. Ribosomal protein S19 deficiency leads to reduced proliferation and increased apoptosis but does not affect terminal erythroid differentiation in a cell line model of Diamond-Blackfan anemia. Stem Cells. 2008;26:323–9. [PubMed: 17962699]
• Morel AS, Joris N, Meuli R, Jacquemont S, Ballhausen D, Bonafe L, Fattet S, Tolsa JF. Early neurological impairment and severe anemia in a newborn with Pearson syndrome. Eur J Pediatr. 2009;168:311–5. [PubMed: 18553104]
• Ohga S, Mugishima H, Ohara A, Kojima S, Fujisawa K, Yagi K, Higashigawa M, Tsukimoto I., Aplastic Anemia Committee Japanese Society of Pediatric Hematology. Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic stem cell transplantation. Int J Hematol. 2004;79:22–30. [PubMed: 14979474]
• Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity. Br J Haematol. 2004;125:243–52. [PubMed: 15059149]
• Parekh S, Perez A, Yang XY, Billett H. Chronic parvovirus infection and G6PD deficiency masquerading as Diamond-Blackfan anemia. Am J Hematol. 2005;79:54–7. [PubMed: 15849759]
• Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168–76. [PMC free article: PMC2268958] [PubMed: 18028431]
• Quarello P, Garelli E, Brusco A, Carando A, Mancini C, Pappi P, Vinti L, Svahn J, Dianzani I, Ramenghi U. High frequency of ribosomal protein gene deletions in Italian Diamond Blackfan anemia patients detected by Multiplex Ligation-dependent Probe Amplification (MLPA) assay. Haematologica. 2012;97:1813–7. [PMC free article: PMC3590087] [PubMed: 22689679]
• Quarello P, Garelli E, Carando A, Brusco A, Calabrese R, Dufour C, Longoni D, Misuraca A, Vinti L, Aspesi A, Biondini L, Loreni F, Dianzani I, Ramenghi U. Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica. 2010;95:206–13. [PMC free article: PMC2817022] [PubMed: 19773262]
• Ramenghi U, Campagnoli MF, Garelli E, Carando A, Brusco A, Bagnara GP, Strippoli P, Izzi GC, Brandalise S, Riccardi R, Dianzani I. Diamond-Blackfan anemia: report of seven further mutations in the RPS19 gene and evidence of mutation heterogeneity in the Italian population. Blood Cells Mol Dis. 2000;26:417–22. [PubMed: 11112378]
• Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL., ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24. [PMC free article: PMC4544753] [PubMed: 25741868]
• Roy V, Perez WS, Eapen M, Marsh JC, Pasquini M, Pasquini R, Mustafa MM, Bredeson CN. Bone marrow transplantation for diamond-blackfan anemia. Biol Blood Marrow Transplant. 2005;11:600–8. [PubMed: 16041310]
• Saladi SM, Chattopadhyay T, Adiotomre PN. Nomimmune hydrops fetalis due to Diamond-Blackfan anemia. Indian Pediatr. 2004;41:187–8. [PubMed: 15004307]
• Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139:1197–207. [PMC free article: PMC7497289] [PubMed: 32596782]
• Taher AT, Iolascon A, Matar CF, Bou-Fakhredin R, de Franceschi L, Cappellini MD, Barcellini W, Russo R, Andolfo I, Tyan P, Gulbis B, Aydinok Y, Anagnou NP, Bencaiova GA, Tamary H, Martinez PA, Forni G, Vindigni R. Recommendations for pregnancy in rare inherited anemias. Hemasphere. 2020;4:e446. [PMC free article: PMC7437563] [PubMed: 32885142]
• Ulirsch JC, Verboon JM, Kazerounian S, Guo MH, Yuan D, Ludwig LS, Handsaker RE, Abdulhay NJ, Fiorini C, Genovese G, Lim ET, Cheng A, Cummings BB, Chao KR, Beggs AH, Genetti CA, Sieff CA, Newburger PE, Niewiadomska E, Matysiak M, Vlachos A, Lipton JM, Atsidaftos E, Glader B, Narla A, Gleizes PE, O'Donohue MF, Montel-Lehry N, Amor DJ, McCarroll SA, O'Donnell-Luria AH, Gupta N, Gabriel SB, MacArthur DG, Lander ES, Lek M, Da Costa L, Nathan DG, Korostelev AA, Do R, Sankaran VG, Gazda HT. The genetic landscape of Diamond-Blackfan anemia. Am J Hum Genet. 2018;103:930–47. [PMC free article: PMC6288280] [PubMed: 30503522]
• Venugopal P, Moore S, Lawrence DM, George AJ, Hannan RD, Bray SC, To LB, D'Andrea RJ, Feng J, Tirimacco A, Yeoman AL, Young CC, Fine M, Schreiber AW, Hahn CN, Barnett C, Saxon B, Scott HS. Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient. Haematologica. 2017;102:e506–e509. [PMC free article: PMC5709125] [PubMed: 28971907]
• Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, Meerpohl J, Karlsson S, Liu JM, Leblanc T, Paley C, Kang EM, Leder EJ, Atsidaftos E, Shimamura A, Bessler M, Glader B, Lipton JM. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:859–76. [PMC free article: PMC2654478] [PubMed: 18671700]
• Vlachos A, Klein GW, Lipton JM. The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2001;23:377–82. [PubMed: 11563775]
• Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;2012;119:3815–9. [PMC free article: PMC3335385] [PubMed: 22362038]
• Willig TN, Draptchinskaia N, Dianzani I, Ball S, Niemeyer C, Ramenghi U, Orfali K, Gustavsson P, Garelli E, Brusco A, Tiemann C, Perignon JL, Bouchier C, Cicchiello L, Dahl N, Mohandas N, Tchernia G. Mutations in ribosomal protein S19 gene and diamond blackfan anemia: wide variations in phenotypic expression. Blood. 1999;94:4294–306. [PubMed: 10590074]